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Vascular microthrombosis associated with increased 
interleukin-6. A severe acute respiratory distress syndrome 
in COVID-19 patients treated with tocilizumab
To the Editor
Thrombosis is an important pathology in 
the deterioration of COVID-19 patient [1–3]. 
In the course of the COVID-19 outbreak at the 
Masih Daneshvari hospital in Iran, we observed 
different cases of cerebrovascular thrombosis, 
deep vein thrombosis, and cases of pulmonary 
microthrombosis despite therapeutic dosing 
with enoxaparin. These thrombotic cases were 
detected by transbronchial lung biopsy mostly in 
COVID-19 infected patients with high interleu-
kin-6 (IL-6) levels. This proposes that respiratory 
failure and hypoxemia might be associated with 
microthrombosis in the small vessels of the pul-
monary tract. Moreover, we detected monocytosis 
accompanied by lymphopenia in most of the 
cases. Monocytosis can additionally potentiate 
the activation of coagulation pathways through 
tissue factor release [4–6].
As a matter of fact, IL-6 is a master influencer 
in inflammatory cytokine drama and correlates 
with a macrophage activation syndrome that 
presents in severe COVID-19 cases [7].
Besides all of the proinflammatory character-
istics of IL-6, we want to point out its probable 
role in thrombosis. IL-6 inhibits ADAMTS-13 ac-
tivity which causes less cleavage of ultra large 
von Willebrand factors (ULVWF) and results 
in a hypercoagulative state [4, 8]. Furthermore, 
IL-6 stimulates a systemic procoagulant effect 
by raising the levels of fibrinogen, plasminogen 
activator inhibitor-1, and C-reactive protein [5].
Seeing as the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) disease does 
not yet have satisfactory treatment options, all 
health care systems are trying various approaches 
to save their patients. Tocilizumab, an IL-6 recep-
tor antagonist, is one of the therapeutic strategies 
in severe cases with increased levels of IL-6 that 
can be used in order to control this cytokine 
release syndrome [7]. Surprisingly, however, we 
detected an increased occurrence in thrombotic 
events in patients who received tocilizumab. In 
spite of tocilizumab’s mechanism of action, there 
was evidence of increased levels of IL-6 after treat-
ment with tocilizumab, which could be a possible 
explanation for the thrombosis [9]. This rise in 
IL-6 level after tocilizumab administration was 
seen in all of the cases in our center.
Consequently, we recommend measuring 
the level of IL-6 following tocilizumab admin-
istration. In the case of an increased level, he-
moperfusion with cytokine-absorbing columns 
and continuous renal replacement therapies are 
suggested in order to decrease the risk of throm-
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bosis. Although, plasmapheresis removes IL-6, it 
may also remove tocilizumab as well, but it can 
be an alternative method if the preferred one is 
not available. 
All possible approaches with the potential to 
decrease IL-6 levels or negate IL-6’s effects can be 
considered for research. For instance, based on ev-
idence in relapsing thrombotic thrombocytopenic 
purpura, N-acetylcysteine may be another option 
for the prevention of thrombosis by reducing the 




1. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and 
thrombotic or thromboembolic disease: implications for pre-
vention, antithrombotic therapy, and follow-up: JACC state-of-
the-art review. J Am Coll Cardiol. 2020; 75(23): 2950–2973, doi: 
10.1016/j.jacc.2020.04.031, indexed in Pubmed: 32311448.
2. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 
in the ICU: vascular dysfunction, thrombosis, and dysregu-
lated inflammation. Intensive Care Med. 2020; 46(6): 1105–
1108, doi: 10.1007/s00134-020-06059-6, indexed in Pubmed: 
32347323.
3. Sungurlu S, Kuppy J, Balk RA. Role of antithrombin III and 
tissue factor pathway in the pathogenesis of sepsis. Crit Care 
Clin. 2020; 36(2): 255–265, doi: 10.1016/j.ccc.2019.12.002, in-
dexed in Pubmed: 32172812.
4. Lee DD, Schwarz MA. Cell-Cell communication breakdown and 
endothelial dysfunction. Crit Care Clin. 2020; 36(2): 189–200, 
doi: 10.1016/j.ccc.2019.11.001, indexed in Pubmed: 32172808.
5. Libby P, Simon DI. Inflammation and thrombosis: the clot 
thickens. Circulation. 2001; 103(13): 1718–1720, doi: 
10.1161/01.cir.103.13.1718, indexed in Pubmed: 11282900.
6. Toussaint S, Gerlach H. Activated protein C for sepsis. N Engl J 
Med. 2009; 361(27): 2646–2652, doi: 10.1056/NEJMct0808063, 
indexed in Pubmed: 20042756.
7. McGonagle D, Sharif K, O’Regan A, et al. The role of cytokines 
including interleukin-6 in COVID-19 induced pneumonia and 
macrophage activation syndrome-like disease. Autoimmun 
Rev. 2020; 19(6): 102537, doi: 10.1016/j.autrev.2020.102537, 
indexed in Pubmed: 32251717.
8. Bernardo A, Ball C, Nolasco L, et al. Effects of inflamma-
tory cytokines on the release and cleavage of the endothe-
lial cell-derived ultralarge von Willebrand factor multim-
ers under flow. Blood. 2004; 104(1): 100–106, doi: 10.1182/
blood-2004-01-0107, indexed in Pubmed: 15026315.
9. Nishimoto N, Terao K, Mima T, et al. Mechanisms and patho-
logic significances in increase in serum interleukin-6 (IL-6) and 
soluble IL-6 receptor after administration of an anti-IL-6 recep-
tor antibody, tocilizumab, in patients with rheumatoid arthritis 
and Castleman disease. Blood. 2008; 112(10): 3959–3964, doi: 
10.1182/blood-2008-05-155846, indexed in Pubmed: 18784373.
10. Cabanillas G, Popescu-Martinez A. N-Acetylcysteine for re-
lapsing thrombotic thrombocytopenic purpura: more evidence 
of a promising drug. Am J Ther. 2016; 23(5): e1277–e1279, 
doi: 10.1097/MJT.0000000000000386, indexed in Pubmed: 
26720166.
